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A functional approach to questions about life, death, and 
phosphorylation 
The success of the family of kinases as targets for small-molecule cancer therapeutics is probably best illustrated by the 
efficacy of the drug Gleevec. In spite of this, the function of many of the kinases in the mammalian genome remains 
unknown. In a recent paper, MacKeigan and colleagues report a functional genetic screen using RNA interference to identify 
kinases and phosphatases involved in programmed cell death (MacKeigan et al., 2005). Functional annotation is a prerequi­
site for selection of new drug targets. Such studies may therefore lay the foundation for the next generation of cancer drugs. 
Phosphorylation of biomolecules is rele- The group of Blenis generated two phosphatases (32%!) caused a greater 
vant for the control of nearly all cellular independent siRNAs for each of 650 than 2-fold increase in apoptosis (named 
processes. Consequently, the enzymes known and putative kinases as well as “survival phosphatases”). Conversely, a 
that are primarily responsible for regula- 222 known and putative phophatases. In screen was performed to identify “cell 
tion of the phosphorylation state of a first cell-based screen, kinases were death phosphatases”: phosphatases that 
biomolecules, the kinases and phos- identified whose suppression caused a act to sensitize cells to apoptosis. Such 
phatases, are attractive targets for drug greater than 2-fold increase in apoptosis phosphatases are potential tumor sup­
development. In oncology, the remark- in HeLa cells (“survival kinases”). pressors, as their inhibition would confer 
able success of Imatinib (also known as Remarkably, 73 of the 650 kinases resistance to apoptosis. To identify these 
Gleevec, a small mole inhibitor of the (11%!) scored as survival kinases in this phosphatases, a screen was set up in 
BCR-ABL tyrosine kinase) and assay, of which CDK6, RPS6KL1, ROR1, which HeLa cells were induced to 
Trastuzumab (also known as undergo apoptosis by treatment 
Herceptin, an antibody targeting with different chemotherapeutic 
the ErbB2 growth factor receptor) agents and the phosphatase 
has sparked an intense search for knockdown library was screened 
kinases involved in cancer-rele­ for inhibition of apoptosis. Among 
vant pathways, such as cell cycle, the 12 cell death phosphatases 
signal transduction, and pro­ identified in this screen are 
grammed cell death (apoptosis). MK-STYX, PPP3CB, ACP6, 
Even though there are no block- PPP4R1L, PTPRS, and PTPRD 
buster drugs targeting protein (Figure 1). 
phosphatases on the market Perhaps more interesting 
today, the interest of drug devel­ from a drug discovery perspective 
opers in this enzyme family has was a fourth screen carried out by 
followed in the slipstream of the MacKeigan et al., in which they 
success of the kinases. In spite of searched for kinases whose inhi­
this, the function of many of the Figure 1. Functional annotation of kinases and phos- bition synergizes with chemother­
over 500 kinases and 200 phos- phatases by RNA interference-based genetic screens in apeutic agents in induction ofhuman cellsphatases in the human genome is apoptosis. Inhibition of such 
Using siRNA-based assays in human cells, a set of 650 knownunderstood poorly, leaving a large and putative kinases as well as 222 known and putative kinases may sensitize cancer 
treasure trove of potential cancer phosphatases were screened for their role in programmed cells to chemotherapeutic agents, 
drug targets untapped.The recent cell death. A total of 73 kinases were identified whose sup- providing a potential basis for 
discovery that RNA interference pression increased apoptosis (“survival kinases”). In a sepa- rational combination therapy. In 
can also be used to suppress rate screen, a set of survival kinases was identified whose this screen, HeLa cells were treat­
gene expression in mammalian suppression sensitized cells to treatment with low-dose ed with low doses of an apopto­chemotherapy. Similar siRNA screens with a 222 member
cells (see Brummelkamp and phosphatase knockdown library allowed the identification sis-inducing chemotherapeutic 
Bernards, 2003, for a review) has of 72 “survival phosphatases” and 12 “death phosphatases.” agent (taxol, cisplatin, or etopo­
provided a tool for large-scale side), and the kinase knockdown 
loss-of-function genetic screens library was screened for kinases 
in higher eukaryotes. Such genetic and NLK were the most potent (Figure 1). whose inhibition increased the rate of 
screens using RNA interference have Since not all siRNAs used in the assay apoptosis induced by the drug. Here one 
already been used in mammalian cells to might be functional, this number may would anticipate the identification of 
identify genes involved in a number of even be an underestimation. Add to that DNA damage signaling kinases such as 
biological processes, including mitosis, the fact that the effects of kinase sup- ATM, ATR, and CHK kinases, which con­
proteasome function, and p53 function. pression on apoptosis may be cell type fer resistance to low levels of DNA dam-
In a new study, MacKeigan and col- dependent and one realizes that it is diffi- age. Surprisingly, however, this was not 
leagues (MacKeigan et al., 2005) use cult to say exactly how many survival the case, perhaps because the screen 
RNA interference to ask which kinases kinases the human genome harbors. was performed in a checkpoint-defective 
and phosphatases are involved in regu- In a related genetic screen, it was tumor cell line. Instead, SGK (an AKT­
lation of programmed cell death. found that inhibition of 72 out of 222 related kinase), mTOR, CDK6, CDK8, 
CANCER CELL : JUNE 2005 503 
P R E V I E W S  
FER, and PINK-1 were found to sensitize 
cells to taxol. Interestingly, mTOR can be 
inhibited by rapamycin, suggesting that 
combining rapamycin and taxol might be 
an effective strategy in cancer therapy. 
The authors also note that PINK-1 maps 
to a genetic locus implemented in familial 
Parkinaon’s disease, which is marked by 
the death of neurons. 
The study by MacKeigan et al. shows 
that inhibition of certain kinases and 
phosphatases can render tumor cells 
more vulnerable to chemotherapeutic 
agents. Does this mean that the kinases 
and phosphatases identified in the pre­
sent study are suitable targets for cancer 
drug discovery? A major question that 
remains unexplored in the present study 
concerns the selectivity of the identified 
targets for cancer cells. Most cancer 
drugs are administered systemically, 
reaching both cancer cells and normal 
cells. If inhibition of the identified targets 
also sensitizes normal cells to 
chemotherapy, not much is gained. In 
addition, most cancer cells have muta­
tions that prevent the induction of apop­
tosis, which could adversely affect the 
way in which cancer cells respond to the 
inhibition of the targets identified here. 
One salient example of such an unex­
pected outcome may be the finding in the 
present study that inhibition of the tumor 
suppressor gene PTEN by siRNA result­
ed in potent induction of cell death in 
cancer cells. Selectivity for cancer cells 
may therefore be more readily obtained 
by identifying “genotype-specific” drug 
targets, i.e., targets whose inhibition is 
only toxic to cells carrying a defined 
(cancer-specific) genetic lesion. This 
concept of “synthetic lethality” in cancer 
drug development was first proposed as 
early as 1997 (Hartwell et al., 1997), but 
has unfortunately remained a subject 
about which more reviews have 
been written than data published. 
Nevertheless, given the frequent occur­
rence of synthetic lethal interactions in 
yeast (Tong et al., 2004), such cancer­
relevant genetic interactions will sooner 
or later be found in mammalian cells 
using techniques similar to those 
employed by MacKeigan et al. 
Functional annotation of mammalian 
kinases and phosphatases is far from 
complete today, and the present study 
shows how powerful RNA interference­
based genetic screens can be to place 
(families of) genes in cancer-relevant 
pathways. An interesting issue is that 
many of the kinases and phoshatases 
identified in the screens described above 
are not overexpressed or mutated in can­
cer. This emphasizes a comment made 
by Stephen Friend at a discussion ses­
sion during the recent 96th AACR meet­
ing in Anaheim that drug developers 
have in the past focused too much on 
genes that are either amplified or mutat­
ed in cancer. Therefore, studies like the 
one by MacKeigan et al. will help reveal 
innovative classes of drug targets that 
were not obvious from more classical 
cancer genetic studies. 
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